AUSTIN, Texas, March 18, 2024 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and wholly owned subsidiary of Centene Corporation (NYSE: CNC), today released its annual community investment report, showcasing a commitment to supporting the health of individuals and families across the state. In 2023, Superior partnered with more than 400 community-based organizations and school districts, participated in 840 events, and contributed nearly $950,000 in grants, sponsorships, and employee donations to further Superior's mission of transforming the health of the communities we serve, one person at a time.
"For 25 years, Superior has prioritized finding ways to support Texas communities and 2023 was no different," said Mark Sanders, president and CEO of Superior HealthPlan. "By working closely with our partners, we have provided funding for innovative programs to help Texans address critical health challenges."
In 2023, Superior funded programs that go beyond traditional healthcare needs and target Non-medical Drivers of Health to improve access to personal care items, food, and mental health resources through the following initiatives:
These partnerships helped improve the health and well-being of individuals throughout Texas while allowing Superior to support and build meaningful relationships within dozens of communities.
To learn more about Superior's investment in Texas communities and other ways the company gives back, visit SuperiorHealthPlan.com.
About Superior HealthPlan
Founded in 1999, Superior HealthPlan is a managed care company that delivers quality health care throughout Texas. Committed to transforming the health of the community, one person at a time, Superior supports active local involvement in all 254 Texas counties with 3,200 employees throughout the state. Superior is a wholly owned subsidiary of Centene Corporation, a leading healthcare enterprise that is committed to helping people live healthier lives. More information on Superior can be found at www.SuperiorHealthPlan.com.
Last Trade: | US$70.83 |
Daily Change: | -1.83 -2.52 |
Daily Volume: | 4,604,229 |
Market Cap: | US$37.260B |
August 29, 2024 July 26, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB